Broker call: Anupam Rasayan (buy)

Goal: ₹1,069

CMP: ₹728.25

We see Anupam Rasayan (Anupam) as a direct beneficiary of the global boom in outsourcing, the government’s emphasis on ‘Make in India’ and the ‘China plus one’ strategy. With its growing chemical capabilities – organic and inorganic – and aggressive capacity addition, Anupam is a strong outsourcing partner for global agrochemical/pharmaceutical players.

Given its large investment of around ₹1,000 crore in place and a recent order adding around ₹475 crore/yr revenue visibility, we estimate a CAGR of 30% in FY22-25 revenue. PAT, meanwhile, would exceed a CAGR of 38% thanks to operating leverage.

This, coupled with a reduction in working capital, would increase RoCE from 11% to 18%.

Main risks: Anupam has a high concentration of customers, with the top ten contributing 80% of revenue. The loss of a customer can result in a loss of business which can harm revenue; Phenol and benzene are the main raw materials, and any sharp increase in RM and end product prices could further increase working capital requirements; and We model revenue ramp-up based on recent won orders and product launches. That said, order cancellations or delays can negatively impact revenue.

About Margie Peters

Check Also

Actions that will come into action on November 11, 2022

Alkem Laboratories said the US health regulator issued three observations after inspecting its St Louis-based …